Arrhythmias & electrophysiologyRandomised controlled trial
Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial
- Randomised controlled trial
- prospective
- open-label
- parallel-assignment
- Enrolled between July 2024 and March 2025
Authors' conclusion
Three-month treatment with dapagliflozin did not reduce the early recurrence of arrhythmia after catheter ablation in patients with persistent AF.
Study context
- Population
- Patients with persistent atrial fibrillation (AF) scheduled for first catheter ablation, without established indications for dapagliflozin (DM, HF or CKD)198 in primary analysis
- Participants
- 200 patients
- Comparison
- Dapagliflozin vs control after catheter ablation
- Dapagliflozinn = 98
- Controln = 100reference
- Primary endpoint
- AF burden, assessed by 7-day single-lead ECG patches
- Follow-up
- 3 months after ablation
Primary result
As reported in the abstract
AF burden
P = 0.48
Secondary outcomes
| Outcome | Dapagliflozin | Control | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Atrial arrhythmia recurrence | 29.6% | 28.0% | 1.11 (0.66–1.86) | P = 0.70 | |
| 0.512Hazard ratio (log scale) |
Changes in quality of life and left atrial diameter
- No significant between-group differences
Original publication
Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. Circulation. Published 9 November 2025. doi:10.1161/circulationaha.125.077447
Summarised from the published abstract; every number is checked against it